Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:CTOR NASDAQ:CVKD NASDAQ:GANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$4.16+3.7%$4.26$3.57▼$12.80$78.56M0.8136,855 shs18,495 shsCTORCitius Oncology$0.98-0.3%$0.81$0.49▼$6.19$87.13M3.56115,079 shs120,565 shsCVKDCadrenal Therapeutics$5.27-0.8%$5.90$4.21▼$16.25$15.23M1.8172,665 shs49,022 shsGANXGain Therapeutics$1.82+2.2%$2.06$1.41▼$4.34$75.92M0.15491,575 shs446,714 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences+3.74%+1.22%-2.58%-12.79%-36.97%CTORCitius Oncology-0.27%+9.26%+26.18%-19.32%+10.56%CVKDCadrenal Therapeutics-0.75%-12.46%+10.02%-4.70%-62.73%GANXGain Therapeutics+2.25%-2.67%-3.70%+0.55%-2.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$4.16+3.7%$4.26$3.57▼$12.80$78.56M0.8136,855 shs18,495 shsCTORCitius Oncology$0.98-0.3%$0.81$0.49▼$6.19$87.13M3.56115,079 shs120,565 shsCVKDCadrenal Therapeutics$5.27-0.8%$5.90$4.21▼$16.25$15.23M1.8172,665 shs49,022 shsGANXGain Therapeutics$1.82+2.2%$2.06$1.41▼$4.34$75.92M0.15491,575 shs446,714 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences+3.74%+1.22%-2.58%-12.79%-36.97%CTORCitius Oncology-0.27%+9.26%+26.18%-19.32%+10.56%CVKDCadrenal Therapeutics-0.75%-12.46%+10.02%-4.70%-62.73%GANXGain Therapeutics+2.25%-2.67%-3.70%+0.55%-2.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 2.00Hold$10.00140.38% UpsideCTORCitius Oncology 2.33Hold$6.00509.57% UpsideCVKDCadrenal Therapeutics 2.00Hold$13.00146.68% UpsideGANXGain Therapeutics 2.60Moderate Buy$8.50367.03% UpsideCurrent Analyst Ratings BreakdownLatest CVKD, CTOR, BHST, and GANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026GANXGain Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.003/27/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)2/19/2026BHSTBioHarvest Sciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$34.51M2.37N/AN/A$1.30 per share3.20CTORCitius Oncology$3.94M22.03N/AN/A$0.54 per share1.82CVKDCadrenal TherapeuticsN/AN/AN/AN/A$0.63 per shareN/AGANXGain TherapeuticsN/AN/AN/AN/A$0.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$11.14M-$0.61N/AN/AN/A-32.27%-136.42%-27.92%N/ACTORCitius Oncology-$24.76M-$0.31N/AN/AN/AN/A-55.19%-23.99%5/20/2026 (Estimated)CVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%N/AGANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%N/ALatest CVKD, CTOR, BHST, and GANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026N/ACTORCitius Oncology-$0.01N/AN/AN/A$7.00 millionN/A5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.11-$0.11N/A-$0.11$8.50 million$8.51 million5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/A4/1/2026Q4 2025BHSTBioHarvest Sciences-$0.11-$0.10+$0.01-$0.10$9.24 million$9.07 million3/31/2026Q4 2025CVKDCadrenal Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A3/26/2026Q4 2025GANXGain Therapeutics-$0.14-$0.11+$0.03-$0.11$0.03 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACTORCitius OncologyN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest Sciences0.103.973.38CTORCitius Oncology0.070.830.32CVKDCadrenal TherapeuticsN/A2.682.68GANXGain Therapeutics0.024.696.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACTORCitius Oncology70.52%CVKDCadrenal Therapeutics7.92%GANXGain Therapeutics11.97%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACTORCitius Oncology7.80%CVKDCadrenal Therapeutics26.09%GANXGain Therapeutics4.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/ACTORCitius OncologyN/A88.28 million81.39 millionN/ACVKDCadrenal Therapeutics42.87 million2.12 millionNot OptionableGANXGain Therapeutics2042.65 million40.88 millionOptionableCVKD, CTOR, BHST, and GANX HeadlinesRecent News About These CompaniesGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate UpdateMay 11, 2026 | finanznachrichten.deGain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 LossMay 11, 2026 | finance.yahoo.comGain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Hits ExpectationsMay 11, 2026 | marketbeat.comGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate UpdateMay 11, 2026 | globenewswire.comGain Therapeutics (GANX) Expected to Announce Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comGain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 7, 2026 | americanbankingnews.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Moderate Buy" by AnalystsMay 7, 2026 | marketbeat.comGain Therapeutics (GANX) Expected to Announce Earnings on WednesdayMay 6, 2026 | marketbeat.comGain Therapeutics (NASDAQ:GANX) Stock Price Up 1.1% - Here's WhyMay 4, 2026 | marketbeat.comGain Flat Ahead of Arizona ConferenceApril 24, 2026 | baystreet.caGain Therapeutics, Inc. to Present Update on Parkinson’s Disease Drug GT-02287 at 3rd International GBA1 Meeting 2026April 24, 2026 | quiverquant.comQGain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026April 24, 2026 | globenewswire.comGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate UpdateMarch 26, 2026 | globenewswire.comGain Therapeutics, Inc. CEO Gene Mack to Speak at 38th Annual ROTH ConferenceMarch 19, 2026 | quiverquant.comQGain Therapeutics to Present at the 38th Annual ROTH ConferenceMarch 19, 2026 | globenewswire.comGain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026March 18, 2026 | globenewswire.comGain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory UpdateMarch 12, 2026 | globenewswire.comWhy Gain Therapeutics, Inc.’s (GANX) Stock Is Up 7.18%February 24, 2026 | aaii.comAGain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 19, 2026 | globenewswire.comGain Therapeutics, Inc. to Participate in Key Events During 44th Annual J.P. Morgan Healthcare Conference WeekJanuary 7, 2026 | quiverquant.comQGain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference WeekJanuary 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026The Nasdaq's Historic Rally Doesn't Mean the Risk Is GoneBy Bridget Bennett | April 19, 2026These 3 Defense Giants Beat Q1 Estimates—So Why Did Their Stocks Still Fall?By Jessica Mitacek | April 22, 2026CVKD, CTOR, BHST, and GANX Company DescriptionsBioHarvest Sciences NASDAQ:BHST$4.16 +0.15 (+3.74%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$4.28 +0.12 (+2.88%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Citius Oncology NASDAQ:CTOR$0.98 0.00 (-0.27%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.98 -0.01 (-0.84%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Cadrenal Therapeutics NASDAQ:CVKD$5.27 -0.04 (-0.75%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$5.22 -0.05 (-0.95%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Gain Therapeutics NASDAQ:GANX$1.82 +0.04 (+2.25%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.86 +0.04 (+2.20%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
